Kyowa Kirin 
Welcome,         Profile    Billing    Logout  
 62 Products   378 Diseases  62 Products   490 Trials   25017 News 
708 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fotivda (tivozanib) / Kyowa Kirin, LG Chem
2021-000050-26: Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Estudio para comparar Tivozanib en combinación con Nivolumab con Tivozanib en monoterapia en sujetos con carcinoma de células renales

Not yet recruiting
3
326
Europe, RoW
Tivozanib, Nivolumab, AV-951, Capsule, hard, Concentrate for solution for infusion, FOTIVDA®, OPDIVO
AVEO Pharmaceuticals, Inc., AVEO PHARMACEUTICALS, INC., AVEO Pharmaceuticals, Inc.
Renal Cell Carcinoma Carcinoma de Células Renales, Kidney cancer Cáncer de riñón, Diseases [C] - Cancer [C04]
 
 
TiNivo-2, NCT04987203: Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

Active, not recruiting
3
343
Europe, Canada, US, RoW
Tivozanib, Nivolumab
AVEO Pharmaceuticals, Inc., Parexel, Bristol-Myers Squibb
Renal Cell Carcinoma
04/24
07/26
STRIKE, NCT06661720: Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Not yet recruiting
3
1040
NA
Pembrolizumab, Keytruda, Tivozanib, Biospecimen Collection, MRI, Computed Tomography, CT Scan, CAT Scan, Biopsy, Questionnaire Administration
Alliance for Clinical Trials in Oncology
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC V8, Stage III Renal Pelvis Cancer AJCC V8
11/37
11/37
NCT01885949: Tivozanib + Enzalutamide in Adv Prostate Cancer

Active, not recruiting
2
5
US
Tivozanib, AV-951, Enzalutamide, MDV-3100
Massachusetts General Hospital, National Comprehensive Cancer Network
Prostate Cancer
12/25
06/26
FORTUNE, NCT06053658: Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Recruiting
2
48
US
Tivozanib, KRN 951, KRN-951, KRN951, UNII-172030934T, AV951, AV951 cpd, Nivolumab, Opdivo, BMS-936558
M.D. Anderson Cancer Center, AVEO Pharmaceuticals, Inc.
Renal Cell Carcinoma
11/26
11/28
DEDUCTIVE, NCT03970616: A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma

Checkmark 1 year OS data from DEDUCTIVE trial in combination with Imfinzi for HCC at ESMO 2022
Jan 2022 - Jan 2022: 1 year OS data from DEDUCTIVE trial in combination with Imfinzi for HCC at ESMO 2022
Hourglass Jan 2021 - Dec 2021 : Data from P2 portion of P1b/2 DEDUCTIVE trial in combination with Imfinzi for advanced HCC
Hourglass Jul 2021 - Dec 2021 : Completion of enrollment of P2 portion of P1b/2 DEDUCTIVE trial in combination with durvalumab for advanced HCC
Checkmark Data from P1b portion of P1b/2 DEDUCTIVE trial in combination with durvalumab for advanced HCC at ASCO GI 2021
More
Terminated
1b/2
27
US
Tivozanib, Fotivda, Durvalumab, Imfinzi
AVEO Pharmaceuticals, Inc., AstraZeneca
Hepatocellular Carcinoma
04/23
04/23
IMMCO-1, NCT05000294: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Recruiting
1/2
29
US
Atezolizumab, Tecentriq, Tivozanib, Fotivda
University of Florida, Genentech, Inc., Aveo Oncology Pharmaceuticals
Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer
06/25
06/26
NCT04645160: Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

Recruiting
1/2
31
US
Tivozanib
National Cancer Institute (NCI)
Cholangiocarcinoma, Bile Duct Neoplasm, Biliary Tract Malignancy
12/26
12/27
lestaurtinib (CEP-701) / Teva, Kyowa Kirin
AALL0631, NCT00557193: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed
3
218
Canada, US, RoW
Asparaginase, ASP-1, Asparaginase II, Asparaginase-E.Coli, Colaspase, Elspar, Kidrolase, L-Asnase, L-ASP, L-Asparaginase, L-Asparagine Amidohydrolase, Laspar, Lcf-ASP, Leucogen, Leunase, MK-965, Paronal, Re-82-TAD-15, Serasa, Spectrila, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin Hydrochloride, Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Echocardiography, EC, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestim, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Laboratory Biomarker Analysis, Lestaurtinib, CEP 701, CEP-701, CEP701, KT-5555, SPM-924, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Mercaptopurine, 3H-Purine-6-thiol, 6 MP, 6 Thiohypoxanthine, 6 Thiopurine, 6-Mercaptopurine, 6-Mercaptopurine Monohydrate, 6-MP, 6-Purinethiol, 6-Thiopurine, 6-Thioxopurine, 6H-Purine-6-thione, 1,7-dihydro- (9CI), 7-Mercapto-1,3,4,6-tetrazaindene, Alti-Mercaptopurine, Azathiopurine, Bw 57-323H, Flocofil, Ismipur, Leukerin, Leupurin, Mercaleukim, Mercaleukin, Mercaptina, Mercaptopurinum, Mercapurin, Mern, NCI-C04886, Puri-Nethol, Purimethol, Purine, 6-mercapto-, Purine-6-thiol (8CI), Purine-6-thiol, monohydrate, Purinethiol, Purinethol, U-4748, WR-2785, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Methylprednisolone, Adlone, Caberdelta M, DepMedalone, Depo Moderin, Depo-Nisolone, Duralone, Emmetipi, Esametone, Firmacort, Medlone 21, Medrate, Medrol, Medrol Veriderm, Medrone, Mega-Star, Meprolone, Methylprednisolonum, Metilbetasone Solubile, Metrocort, Metypresol, Metysolon, Predni-M-Tablinen, Prednilen, Radilem, Sieropresol, Solpredone, Summicort, Urbason, Veriderm Medrol, Wyacort, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Pegaspargase, L-Asparaginase with Polyethylene Glycol, Oncaspar, Oncaspar-IV, PEG-Asparaginase, PEG-L-Asparaginase, PEG-L-Asparaginase (Enzon - Kyowa Hakko), PEGLA, Polyethylene Glycol L-Asparaginase, Polyethylene Glycol-L-Asparaginase, Pharmacological Study, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Therapeutic Hydrocortisone, Aeroseb-HC, Barseb HC, Barseb-HC, Cetacort, Cort-Dome, Cortef, Cortenema, Cortifan, Cortisol, Cortispray, Cortril, Dermacort, Domolene, Eldecort, Hautosone, Heb-Cort, Hydrocortisone, Hydrocortone, Hytone, Komed-HC, Nutracort, Proctocort, Rectoid, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Children's Oncology Group, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia
09/17
06/24
Nourianz (istradefylline) / Kyowa Kirin
NCT05885360: Istradefylline Effect Protocol on Parkinson's Disease Tremor

Active, not recruiting
4
27
US
Istradefylline Pill, NOURIANZ
Georgetown University, Kyowa Kirin, Inc.
Parkinson Disease, Tremor
09/24
12/24
NCT05333549: Istradefylline for Parkinson Disease With Cognitive Impairment

Recruiting
2
10
US
Istradefylline medication
Virginia Commonwealth University, Kyowa Kirin, Inc.
Parkinson Disease, Cognitive Impairment
07/25
07/25
NCT05377424: Adenosine 2A Receptor Antagonism and AIH in ALS

Recruiting
1/2
40
US
Consume 20mg of istradefylline, Nourianz, Low Oxygen therapy, Acute Intermittent Hypoxia, AIH, Placebo counterpart to the istradefylline drug, Placebo, SHAM counterpart to low oxygen therapy., SHAM acute intermittent hypoxia, SHAM-AIH
University of Florida, ALS Association
ALS
12/25
12/25
NCT05217498: Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury

Not yet recruiting
1/2
40
US
Istradefylline, KW6002, Nourianz, low oxygen therapy, acute intermittent hypoxia
Randy Trumbower, PT, PhD
Spinal Cord Injuries, Myelopathy
12/26
06/27
NCT05182151: Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.

Terminated
N/A
8
US
Istradefylline 40 mg
Medical University of South Carolina, Kyowa Kirin, Inc.
Apathy, Parkinson Disease
12/23
12/23
Truseltiq (infigratinib) / BridgeBio, Pfizer, Xediton Pharma
PROOF 301, NCT03773302 / 2018-004004-19: Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Checkmark BridgeBio terminated ongoing phase 3 clinical trial for treating 1L cholangiocarcinoma as a result of withdrawal of NDA
Oct 2022 - Oct 2022: BridgeBio terminated ongoing phase 3 clinical trial for treating 1L cholangiocarcinoma as a result of withdrawal of NDA
Checkmark Fast track and orphan drug designation for the treatment of cholangiocarcinoma
Jan 2020 - Jan 2020: Fast track and orphan drug designation for the treatment of cholangiocarcinoma
Terminated
3
48
Europe, Canada, US, RoW
BGJ398, Infigratinib, Gemcitabine, Cisplatin
QED Therapeutics, Inc., Helsinn Healthcare SA
Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
03/23
03/23
PROPEL3, NCT06164951: A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents with Achondroplasia

Enrolling by invitation
3
110
Europe, Canada, US, RoW
Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day
QED Therapeutics, Inc.
Achondroplasia
12/25
04/26
NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations

Checkmark NMPA cleared CTA to conduct the Phase 2a trial for metastatic gastric cancer or GE junction adenocarcinoma with FGFR2 gene amplification
Dec 2020 - Dec 2020: NMPA cleared CTA to conduct the Phase 2a trial for metastatic gastric cancer or GE junction adenocarcinoma with FGFR2 gene amplification
Recruiting
2a
80
RoW
Infigratinib, BGJ398
LianBio LLC
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor
12/22
12/23
2021-001855-15: A study to evaluate long-term Infigratinib in children with Achondroplasia Un estudio para evaluar Infigratinib a largo plazo en niños con acondroplasia

Not yet recruiting
2
280
Europe
Infigratinib, BGJ398 (also known as BBP-831), Tablet
QED Therapeutics, Inc., QED Therapeutics, Inc.
Achondroplasia in Children Acondroplasia en niños, Disproportionate short stature with rhizomelia (shortened proximal limbs). Estatura desproporcionádamente corta con rizomelia (miembros proximales acortados), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
LOGIC-2, NCT02159066 / 2013-004552-38: LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Checkmark Clinical activity and tolerability data from LOGIC-2 trial of binimetinib, encorafenib with a third agent (LEE011, BKM120, BFJ398 or INC280) combination for BRAF melanoma at ECC 2015
Sep 2015 - Sep 2015: Clinical activity and tolerability data from LOGIC-2 trial of binimetinib, encorafenib with a third agent (LEE011, BKM120, BFJ398 or INC280) combination for BRAF melanoma at ECC 2015
Checkmark From LOGIC-2 trial for advanced BRAF V600 melanoma at ECC 2015
Sep 2015 - Sep 2015: From LOGIC-2 trial for advanced BRAF V600 melanoma at ECC 2015
Completed
2
158
Europe, Canada, US, RoW
LGX818, MEK162, LEE011, BGJ398, BKM120, INC280
Pfizer
Melanoma
01/23
01/23
PROPEL 2, NCT04265651 / 2019-002954-21: Study of Infigratinib in Children with Achondroplasia

Active, not recruiting
2
84
Europe, Canada, US, RoW
Infigratinib 0.016 mg/kg, Infigratinib 0.032 mg/kg, Infigratinib 0.064 mg/kg, Infigratinib 0.128 mg/kg, Infigratinib 0.25 mg/kg
QED Therapeutics, Inc.
Achondroplasia
10/24
12/24
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Terminated
2
6
RoW
Infigratinib, BGJ398, BBP-831
LianBio LLC
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
05/24
05/24
NCT04233567: Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

Checkmark Decision to withdraw NDA for Truseltiq which was approved for adult patients with unresectable locally advanced/metastatic 2L cholangiocarcinoma with FGFR2 fusion or other rearrangement
Oct 2022 - Oct 2022: Decision to withdraw NDA for Truseltiq which was approved for adult patients with unresectable locally advanced/metastatic 2L cholangiocarcinoma with FGFR2 fusion or other rearrangement
Checkmark Health Canada approved for the treatment of adults unresectable locally advanced or metastatic 2L cholangiocarcinoma
Sep 2021 - Sep 2021: Health Canada approved for the treatment of adults unresectable locally advanced or metastatic 2L cholangiocarcinoma
Checkmark Approved for previously-treated locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement
More
Active, not recruiting
2
17
US
Infigratinib, 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea, BGJ-398, BGJ398
Sameek Roychowdhury
Advanced Malignant Solid Neoplasm, Cholangiocarcinoma, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
12/24
12/24
NCT05514912: Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Withdrawn
2
40
NA
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Infigratinib Phosphate, N'-(2,6-Dichloro-3,5-dimethoxyphenyl)-N-(6-(4-(4-ethylpiperazin-1-yl)anilino)pyrimidin-4-yl)-N-methylurea Phosphate (1:1), Truseltiq, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel
Emory University, National Cancer Institute (NCI)
Resectable Intrahepatic Cholangiocarcinoma, Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8, Stage I Intrahepatic Cholangiocarcinoma AJCC v8, Stage II Intrahepatic Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8
06/27
06/27
NCT05145010: Extension Study of Infigratinib in Children with Achondroplasia (ACH)

Enrolling by invitation
2
300
Europe, Canada, US, RoW
Infigratinib
QED Therapeutics, Inc.
Achondroplasia
12/31
02/32
NEWEL, NCT05222165: Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

Withdrawn
1b/2
51
Europe, Canada, US
Infigratinib, BGJ398
Helsinn Healthcare SA, Labcorp Drug Development Inc
Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma
12/22
12/22
2021-005614-34: Study of Infigratinib in Subjects with Advanced Solid and CNS Tumorsor Recurrent or Progressive Low-Grade Glioma with Selected FGFR1-3 Alterations

Not yet recruiting
1/2
51
Europe
Infigratinib hard gelatin sprinkle capsules 18 mg, Infigratinib hard gelatin sprinkle capsules 25 mg, Infigratinib hard gelatin locking capsules 75 mg, BGJ398, BBP-831, Capsule, hard, TRUSELTIQ (infigratinib hard gelatin locking capsules 25 mg), TRUSELTIQ (infigratinib hard gelatin locking capsules 100 mg)
Helsinn Healthcare SA, Helsinn Healthcare SA
Advanced solid and CNS tumors with selected FGFR1-3 mutations or fusions/rearrangements, inclusive of recurrent or progressive low-grade glioma (LGG) with selected FGFR1-3 mutations or fusions/rearrangements., Advanced solid and central nervous system tumors (brain tumors) that is coming back after treatment (recurrent) or getting worse (progressive)., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04228042: Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer

Completed
1/2
15
US
Infigratinib, 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea, BGJ-398, BGJ398, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Surgical Procedure, Operation, Surgery, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Renal Pelvis and Ureter Urothelial Carcinoma
04/24
04/24
NCT04424966: Infigratinib in Recurrent High-Grade Glioma Patients

Terminated
1
7
US
Infigratinib
Nader Sanai, Ivy Brain Tumor Center, Barrow Neurological Institute, QED Therapeutics
Glioma, Glioblastoma, GBM
04/23
04/23
NCT05510427: Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Withdrawn
1
28
NA
Infigratinib, Atezolizumab, Bevacizumab
M.D. Anderson Cancer Center, Helsinn Healthcare SA
Cholangiocarcinoma, Liver Cancer
08/23
08/23
NCT02657486: BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

Active, not recruiting
N/A
4
US
BGJ398
Memorial Sloan Kettering Cancer Center
Bladder Cancer, Non-Muscle-Invasive Urothelial Carcinoma
01/25
01/25
saxagliptin / Generic mfg.
ChiCTR-TRC-13003858: The study of Dipeptidyl peptidase-IV inhibitor's efficacy and safety when it is applied on type 2 diabetes whose blood suger was poorly controlled with original oral antidiabetic drug

Completed
4
40
 
saxagliptin vs Vildagliptin
The First Hospital, Guangzhou Medical University; The First Hospital, Guangzhou Medical University, Pharmaceutical Association
Type 2 diabetes mellitus
 
 
ChiCTR-IPR-15006340: Renal effects of Saxagliptin and Linagliptin in diabetic nephropathy: A randomized, double-blind, head to head study.

Not yet recruiting
4
74
 
with Saxagliptin treatment ;with Linagliptin treatment
Tianjin Medical University; Level of the institution：, The National Natural Science General Program
Diabetic Nephropathy
 
 
2012-002407-18: DPP4inhibitors in Type 1 Diabetes

Ongoing
4
12
Europe
Saxagliptin, Onglyza, Onglyza
University of Dundee and NHS Tayside, NHS Tayside, Tenovus Scotland,
Type 1 Diabetes
 
 
2014-003788-39: Effect of Saxagliptin in Addition to Dapagliflozin and Metformin on Insulin Resistance, Islet Cell Dysfunction, and Metabolic Control in Subjects with Type 2 Diabetes Mellitus on Previous Metformin Treatment

Ongoing
4
24
Europe
Forxiga, Onglyza, Forxiga, Onglyza
Profil Mainz GmbH & Co KG, Astra Zeneca
Type 2 Diabetes mellitus
 
 
ChiCTR2000040826: A comparative study of acarbose, vildagliptin and saxagliptin intended for better efficacy and safety on type 2 diabetes mellitus treatment

Completed
4
90
 
Acarbose tablets orally (100 mg/tablet, Bayer, Leverkusen, Germany) 3 times each day with 100 mg each time ;vildagliptin tablets orally (50 mg/tablet, AstraZeneca, Cambridge, London, England) 2 times each day with 50 mg each time ;saxagliptin tablets orally (5 mg/tablet, AstraZeneca, Cambridge, London, England) one time each day with 5 mg each time
Affiliated Hospital of Qiingdao University; Affiliated Hospital of Qiingdao University, Self-financing
Type 2 diabetes mellitus
 
 
ChiCTR-IPR-17010329: Effect of saxagliptin on bone metabolism in type 2 diabetic

Recruiting
4
80
 
Saxagliptin ;placebo
Nanjing First Hospital, Nanjing Medical University; Nanjing First Hospital, Nanjing Medical University, Major Project of Technological Development of Nanjing Medical University
type 2 diabetes
 
 
ChiCTR1800018292: Study for the effect of dapagliflozin combined with insulin pump in type 2 diabetes mellitus

Recruiting
4
87
 
dapagliflozin 10mg/d+ insulin pump + Saxagliptin 5mg/d or Liraglutide 1.2mg/d ;insulin pump + Saxagliptin 5mg/d or Liraglutide 1.2mg/d.
Teda International Cardiovascular Hospital; Teda International Cardiovascular Hospita, Tianjin Binhai New Area Health and Family Planning Commission science and technology project
Diabetes
 
 
ChiCTR-IPR-17014233: saxagliptin protects early nephropathy of type 2 diabetes by increasing SDF-1α level: A mechanistic study

Recruiting
4
160
 
saxagliptin ;acarbose
Tianjin Medical University Metabolic Diseases Hospital; Tianjin Medical University Metabolic Diseases Hospital, Tianjin Medical University
Diabetic nephropathy
 
 
ChiCTR-IPR-17010318: The influence of saxagliptin as add-on therapy to premixed insulin on the glucolipid metabolism in elderly, insulin-requiring patients with type 2 diabetes mellitus.

Recruiting
4
60
 
saxagliptin plus to insulin ;insulin
Peking University Shougang Hospital; Peking University Shougang Hospital, scientific research fund of Peking University Shougang Hospital in 2016
type 2 diabetes
 
 
ChiCTR2000029688: Effect of Saxagliptin on Cognitive Function in Diabetes Patients After Stroke

Not yet recruiting
4
215
 
Saxagliptin ;Glezit
Liaocheng People's Hospital; Liaocheng People's Hospital, ZR2017PH054 Natural Science Foundation of Shandong Province 2017WS327 Shandong Medicine and Health Science Technology Development Program
Diabetes
 
 
NCT03199053 / 2015-005042-66: Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old

Completed
3
256
Europe, Canada, US, RoW
Dapagliflozin, Forxiga, Saxagliptin, Onglyza, Placebo
AstraZeneca
Diabetes Mellitus, Type 2
02/23
01/24
ChiCTR-IIR-16008856: Bioequivalence study of Saxagliptin tablets to healthy Chinese volunteers in a single-dose study

Not yet recruiting
1
56
 
T-R ;R-T ;T-R ;R-T
Beijing Shijitan Hospital Capital Medical University; Jiangsu Aosaikang Pharmaceutical Co. Ltd., Jiangsu Aosaikang Pharmaceutical Co. Ltd.
diabetes
 
 
ChiCTR-OON-17011950: Saxagliptin upregulates nesfatin-1 secretion in type 2 diabetes mellitus: a 52-week controlled trial

Completed
N/A
102
 
Saxagliptin ;None DPP-4 Inhibitors
Jiangsu Jiankang Vocational College; Jiangsu Jiankang Vocational College, college
diabetes
 
 
ChiCTR-IOR-15005939: Efficacy and safety of saxagliptin-initiate new stepwise triple anti-hyperglycemic therapy in drug-naive aging T2DM patients

Not yet recruiting
N/A
416
 
Saxagliptin-Met-basal insulin ;Met-DiaMicron MR-basal insulin
Fuwai Hospital; Fuwai Hospital, AstraZeneca
diabetes mellitus
 
 
ChiCTR1800015195: Saxagliptin up-regulates nesfatin-1 secretion and inhibits erythrocyte aldose reductase activity in newly diagnosed type 2 diabetes

Completed
N/A
46
 
Saxagliptin ;acarbose
Jiangsu Jiankang Vocational College; JIANGSU JIANKANG VOCATIONAL COLLEGE, college level
diabetes
 
 
ChiCTR1800018608: Efficacy and Mechanism of Saxagliptin on Patients with Type 2 Diabetes Mellitus and Psoriasis.

Not yet recruiting
N/A
60
 
Conventional treatment ;Conventional and Saxagliptin treatment
Affiliated Hospital of Weifang Medical Univeisity; Affiliated Hospital of Weifang Medical University, National Natural Science Foundation of China
psoriasis
 
 
NCT02244164: Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

Terminated
N/A
5
Europe
Incretinomimetics, - exenatide (Byetta®), - liraglutide (Victoza®), - lixisenatide (Lyxumia®), - exenatide extended-release (Bydureon®)., DPP-4 inhibitors, - sitagliptine (Januvia®), - vildagliptine (Galvus®), - saxagliptine (Onglyza®), - linagliptine (Trajenta®).
Erasme University Hospital
Type 2 Diabetes, Incretinomimetics, Pancreas
02/23
02/23
HARRP, NCT06099067: Harmonizing RCT-Duplicate Emulations In A Real World Replication Program

Completed
N/A
239990
Europe
Canagliflozin, DPP4 inhibitor, Liraglutide, Saxagliptin, 2nd generation Sulfonylurea
AstraZeneca
Type 2 Diabetes Mellitus
08/23
08/23
NCT05347459: Cognitive Protective Effect of Newer Antidiabetic Drugs

Recruiting
N/A
100
RoW
Dapagliflozin, Empagliflozin, Canagliflozin, Sitagliptin, Saxagliptin, Linagliptin, Vildagliptin
Alexandria University
Type 2 Diabetes
12/23
12/23
ON TARGET DM, NCT05073692: Comparison of Type 2 Diabetes Pharmacotherapy Regimens

Recruiting
N/A
270000
US
SU, DPP4, SGLT2i, GLP-1RA, SGLT2i or GLP-1RA, Linagliptin (DPP4), Exenatide (GLP-1RA), Liraglutide (GLP-1RA), Empagliflozin (SGLT2i), Glimepiride (SU), Glipizide (SU), Glimepiride (SU) or Glipizide (SU), SU or DPP4 (excluding saxagliptin and alogliptin), Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
Kaiser Permanente, Geisinger Clinic, Henry Ford Health System, HealthPartners Institute, Patient-Centered Outcomes Research Institute
Type 2 Diabetes Mellitus, Cardiovascular Diseases
12/24
08/25
Rectiv (nitroglycerin) / Kyowa Kirin, Endo
ACTRN12611000455965: Does Glyceryl Trinitrate (Rectogesic) reduce post Operative pain in Stapled Haemorrhoidectomy?: A Randomized Controlled Trial

Active, not recruiting
3/4
200
 
Trent Cross, James Cook University, The Townsville Hospital, Queensland Health
Haemorrhoids and the effect of Rectogesic on post operative pain
 
 
2010-018506-37: Ensayo clínico randomizado, de grupos paralelos para estudiar la eficacia y seguridad de diltiazem frente a nitroglicerina en pacientes con fisura anal.

Ongoing
3
216
Europe
Diltiazem pomada al 2%, RECTOGESIC 4 mg/g pomada rectal, RECTOGESIC 4 mg/g pomada rectal
Mª Isabel Fernández García
Fisura anal
 
 
Jesduvroq (daprodustat) / GSK, Kyowa Kirin
ROQ-IT, NCT05951192: A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease

Completed
4
161
US
Daprodustat, JESDUVROQ
USRC Kidney Research, GlaxoSmithKline
Anemia, Renal Insufficiency, Chronic, Renal Anemia
02/24
02/24
2021-002013-34: A trial of daprodustat to treat anemia in children and young people aged 3 months to <18 years with chronic kidney disease. Un estudio de Daprodustat para tratar la anemia en niños y jóvenes entre 3 meses y <18 años para tratar la enfermedad renal crónica.

Ongoing
3
120
Europe, RoW, Canada, Japan, US
Daprodustat, GSK1278863, Film-coated tablet
GlaxoSmithKline Research & Development Limited, GlaxoSmithKline Research & Development Limited
Anemia associated with chronic kidney disease (CKD) Anemia asociada con enfermedad renal crónica (ERC), Anemia associated with chronic kidney disease (CKD) Anemia asociada con la enfermedad renal crónica (ERC), Body processes [G] - Physiological processes [G07]
 
 
ASCEND-P, NCT05682326 / 2021-002013-34: Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric

Active, not recruiting
3
75
Japan, US, RoW
Daprodustat
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited, GSK Research & Development Limited
Anaemia
07/30
07/30
2017-002268-42: Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat –Forearm Blood Flow (ASCEND-FBF)

Not yet recruiting
2
62
Europe
daprodustat 1mg, daprodustat 2mg, daprodustat 4mg, Darbepoetin alfa, Tablet, Solution for injection in pre-filled syringe, Aranesp
GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline R&D
anemia associated with chronic kidney disease, anemia associated with chronic kidney disease, Body processes [G] - Physiological processes [G07]
 
 
Rapinyl (fentanyl) / Orexo, Zydus Lifesci
2013-003319-23: comparison between sublingual fentanyl and subcutaneous morphine in patients with sever episode of cancer pain

Ongoing
4
112
Europe
sublingual fentanyl, N02AB03, Sublingual tablet, Abstral
Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori
pain due to cancer dolore da cancro, cancer pain, Diseases [C] - Cancer [C04]
 
 
2013-003707-18: Absorption of sublingual delivered fentanyl (Abstral®) in head and neck cancer patients treated with curatively aimed chemo-radiotherapy Absorptie van sublinguaal fentanyl (abstral) bij pt met hoofdhalskanker die behandeld worden met chemoradiatie

Ongoing
4
13
Europe
Abstral, PL 16508/0031, Abstral, Abstral
head and neck cancer patients treated with chemo-radiotherapy hoofdhalskankerpatienten die behandeld worden met chemoradiatie
 
 
2018-002606-31: Sublingual versus intravenous Fentanyl in patients with acute trauma - a randomized, double-blind, double-dummy study to demonstrate non-inferiority TraumaPACT Sublingual appliziertes Fentanyl im Vergleich zur i.v.-Gabe bei akutem Trauma – eine randomisierte, 2-armige, doppelblinde, double-dummy Nicht-Unterlegenheitsstudie

Not yet recruiting
3
340
Europe
Abstral, Fentanyl, Sublingual tablet, Solution for injection, Abstral, Fentanyl
Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg and its Commercial, German Ministry of Defence
Trauma with acute pain, Trauma and acute pain, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
 
 
NCI-2018-01124, NCT03214510: Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery

Recruiting
3
96
US
Bupivacaine, AH 250, Fentanyl, Abstral, Duragesic, Hydromorphone Hydrochloride, Dilaudid, Dilaudid HP, Dimorphone, Exalgo, Hydromorphone, Hydrostat, Hymorphan, Laudicon, Novolauden, Implanted Medical Device, IMPLANTED, Liposomal Bupivacaine, Bupivacaine Liposome Injectable Suspension, Exparel, Questionnaire, Questionnaires
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Liver and Intrahepatic Bile Duct Disorder
07/26
07/26
2016-001520-66: Not applicable Non applicable

Not yet recruiting
2
180
Europe
Nasal spray, Sublingual tablet, PECFENT, Abstral
UNICANCER, Laboratoire Kiowakirin
Cancer patient Patient suivi et/ou traité pour une maladie cancéreuse, Cancer patient Patient atteint d'un cancer, Diseases [C] - Cancer [C04]
 
 
Lazanda (fentanyl) / Assertio, Kyowa Kirin
2014-003156-31: Etude de la tolérance du fentanyl intranasal (Pecfent®) dans le traitement des douleurs procédurales chez la personne âgée, avec ou sans traitement de fond.

Not yet recruiting
4
60
Europe
FENTANYL, Nasal spray, solution, PecFent
CHU GRENOBLE
Traitement des patients âgés de plus de 75 ans, hospitalisés en service de gériatrie et nécessitant un soin ou une réhabilitation et manifestant une douleur EVA ≥ 4., Traitement des patients âgés de plus de 75 ans, hospitalisés en service de gériatrie et nécessitant un soin ou une réhabilitation et manifestant une douleur EVA ≥ 4., Health Care [N] - Environment and Public Health [N06]
 
 
Siliq (brodalumab) / Bausch Health
2018-000097-30: Efficacy of brodalumab in patients with psoriasis with failure of other anti-IL-17 treatments Effekt af brodalumab hos patienter, som har haft svigt af anti-IL-17A-behandling

Ongoing
4
20
Europe
brodalumab, Solution for injection in pre-filled syringe, Kyntheum
Herlev and Gentofte Hospital, LEO Pharma A/S
Psoriasis Psoriasis, Psoriasis Psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
2018-001021-10: A Clinical study with brodalumab for patients suffering from psoriasis and not benefitting the TNF-alpha treatment.

Ongoing
4
90
Europe
Injection, Kyntheum
Sahlgrenska University Hospital, Leo Pharma Ab
Moderate to severe plaque psoriasis, Psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
2019-004230-42: Dose reduction of IL17 and IL23 inhibitors for psoriasis Dosis reductie van IL17 en IL23 remmers voor psoriasis

Not yet recruiting
4
244
Europe
secukinumab, ixekizumab, brodalumab, risankizumab, tildrakizumab, guselkumab, Injection, Cosentyx, Taltz, Kyntheum, Skyrizi, Ilumetri, Tremfya
Radboudumc, ZonMw, KCE
psoriasis psoriasis, psoriasis psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
2021-003785-13: Trial to investigate efficacy of brodalumab in eczematized psoriasis

Not yet recruiting
4
15
Europe
Brodalumab, Injection, Brodalumab
Karolinska Universitetssjukhuset, Leo Pharma
eczematized psoriasis, Psoriasis with eczema like features, Diseases [C] - Immune System Diseases [C20]
 
 
NCT04622033: Brodalumab in Palmoplantar Psoriasis

Not yet recruiting
4
10
NA
Brodalumab
First OC Dermatology
Palmoplantar Psoriasis
11/21
05/22
BeNeBio, NCT04340076: Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

Active, not recruiting
4
244
Europe
Secukinumab, Cosentyx, Ixekizumab, Taltz, Brodalumab, Kyntheum, Guselkumab, Tremfya, Risankizumab, Skyrizi, Tildrakizumab, Ilumetri, Bimekizumab, Bimzelx
Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Belgium Health Care Knowledge Centre, University Hospital, Ghent
Psoriasis, Psoriasis Vulgaris
12/25
12/25
ChiCTR2000039699: A Phase 4 Clinical Study to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy of Brodalumab (KHK4827) in Subjects with Moderate to Severe Plaque Psoriasis

Recruiting
4
400
 
Brodalumab Injection (KHK4827) 210 mg Q2W ;Placebo
Peking University People's Hospital; Kyowa Kirin Co., Ltd., self financing
The treatment of moderate to severe Plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy
 
 
NCT03240809: An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects

Recruiting
4
16
US
Brodalumab
Bausch Health Americas, Inc.
Psoriasis
07/24
07/24
ADJUST, NCT04306315 / 2017-004998-13: Adjusted Brodalumab Dose Compared with Standard Brodalumab Dose in Subjects with Moderate-to-severe Plaque Psoriasis and ≥120 Kg Body Weight

Recruiting
4
384
Europe, RoW
Brodalumab
LEO Pharma, LEO Pharma A/S
Psoriasis Vulgaris
09/25
01/26
NCT03957681: A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis

Checkmark Safety and efficacy of LUMICEF in subjects with systemic sclerosis at EULAR 2022
Jun 2022 - Jun 2022: Safety and efficacy of LUMICEF in subjects with systemic sclerosis at EULAR 2022
Active, not recruiting
3
100
Japan
KHK4827, Placebo
Kyowa Kirin Co., Ltd.
Moderate to Severe Systemic Sclerosis
10/20
02/25
NCT04061252: A Study of KHK4827 in Subjects With Palmoplantar Pustulosis

Completed
3
126
Japan
KHK4827, Placebo
Kyowa Kirin Co., Ltd.
Palmoplantar Pustulosis
08/21
08/22
EMBRACE 1, NCT04305327 / 2019-001868-30: Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis

Terminated
3
12
Europe
Brodalumab, Kyntheum®, Ustekinumab, Stelara®, Placebo
LEO Pharma
Psoriasis
05/23
05/23
NCT04368403: A Study of KHK4827 in Patients With Systemic Sclerosis

Active, not recruiting
1
8
Japan
KHK4827
Kyowa Kirin Co., Ltd.
Systemic Sclerosis
01/19
02/25
NCT06673329: Brodalumab in the Treatment of Immune-Related Adverse Events

Recruiting
1
11
US
Brodalumab, SILIQ, CT scan
Brian Henick, MD, Bausch Health
Breast Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer, Thyroid Cancer, Gynecologic Cancer, Pancreatic Cancer, Stomach Cancer, Brain Tumor, Colon Cancer, Rectal Cancer, Head and Neck Cancer, Oral Cancer, Liver Cancer, Skin Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
05/26
11/26
BOMOGUMIP, NCT04680624: Role of Brodalumab in the Modulation of Gut Microbiome in Psoriatic Patients

Not yet recruiting
N/A
15
NA
Fecal sample collection
Association pour la Recherche Clinique et Immunologique
Psoriasis
01/22
01/22
BIOLOPTIM-BRO, NCT04080635: Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients

Recruiting
N/A
100
Europe
Venapuncture, Patient questionnaires
University Hospital, Ghent, KU Leuven, University Ghent
Psoriasis Vulgaris
12/24
12/24
CARE, NCT05132231: Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity

Active, not recruiting
N/A
394
Canada
Brodalumab, Matched cohort
Bausch Health Americas, Inc.
Psoriasis
02/25
02/25
NCT03358693: Molecular Signatures in Inflammatory Skin Disease

Recruiting
N/A
300
Europe
Ustekinumab, Infliximab, Secukinumab, Dupilumab, Brodalumab, Ixekizumab, Baricitinib, Abrocitinib, Upadacitinib, Tralokinumab
Prof. Dr. Stephan Weidinger
Atopic Dermatitis, Psoriasis
12/27
12/28
NCT03254667: LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis

Enrolling by invitation
N/A
3500
US
Brodalumab, Comparator Drug (non-biologic IL-17 inhibitors)
Bausch Health Americas, Inc.
Psoriasis
11/30
11/31
tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
2009-015400-26: MULTICENTER PHASE 2 TRIAL OF ARQ 197 FOR SUBJECTS WITH RELAPSED OR REFRACTORY GERM CELL TUMORS

Ongoing
2
41
Europe, RoW
ARQ197, Capsule*
Daiichi Sankyo Pharma Development
Germ cell tumors (GCT) including testicular and non-central nervous system (non-CNS) extragonadal types.
 
 
NCT01542996: ARQ197 in Metastatic Triple-Negative Breast Cancer

Active, not recruiting
2
40
US
ARQ 197
Dana-Farber Cancer Institute
Breast Cancer
08/13
 
2014-002497-37: TIvantinib as Maintenance treatment in Extended Small-cell lung cancer Tivantinib come terapia di mantenimento nel carcinoma polmonare a piccole cellule avanzato

Ongoing
2
66
Europe
Tivantinib, ARQ197, Tablet
Istituto Oncologico del Veneto IRCCS – UOC Oncologia Medica 2, AIRC- Italian Cancer Research Association
Small Cell Lung Cancer (SCLC) after first-line platinum plus etoposide therapy Carcinoma polmonare a piccole cellule (SCLC) dopo terapia in prima linea con platino e etoposide, Lung Cancer Carcinoma polmonare, Diseases [C] - Cancer [C04]
 
 
quisovalimab (AVTX-002) / Avalo Therap
NCT05288504: A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.

Completed
2
91
US
AVTX-002, CERC-002, AEVI-002, MDGN-002, Placebo
Avalo Therapeutics, Inc.
Non-Eosinophilic Asthma
05/23
05/23
Fasenra (benralizumab) / AstraZeneca
2018-000578-31: Impact of benralizumab treatment on asthma Einfluss einer Benralizumab-Behandlung auf Asthma

Not yet recruiting
4
20
Europe
Fasenra, Fasenra
University Medicine Rostock, AstraZeneca
Eosinophilic Asthma Eosinophilic asthma, Asthma Asthma, Body processes [G] - Immune system processes [G12]
 
 
2018-002292-18: Benralizumab responders and eosinophilic asthma patients

Not yet recruiting
4
60
Europe
Solution for injection, Fasenra (benralizumab)
University Hospital of Montpellier, AstraZeneca
The study population corresponds to severe eosinophilic asthma patients La maladie sur laquelle porte l'étude est l'asthme sévère avec éosinophilie, The study population corresponds to severe eosinophilic asthma patients, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2018-003699-11: Benralizumab Exacerbation Study

Not yet recruiting
4
150
Europe
Fasenra, Not applicable, Solution for injection in pre-filled syringe, Solution for injection in pre-filled pen, Fasenra
NHS Greater Glasgow and Clyde, AstraZeneca
Severe Eosinophilic Asthma, Severe asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2017-003665-10: Benralizumab and lung micro-organisms (BALM)

Not yet recruiting
4
20
Europe
Fasenra, N/A, Suspension for injection in pre-filled syringe, Fasenra
Royal Brompton and Harefield NHS Foundation Trust
Severe Eosinophilic Asthma, Asthma which requires high-dose treatments to maintain disease control (or which remains uncontrolled despite this), with evidence of inflammation involving eosinophils (a type of white blood cell), Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2020-002165-34: Predictive Signature of Benralizumab Response Signature prédictive de la réponse au Benralizumab

Not yet recruiting
4
220
Europe
Benralizumab, Solution for injection in pre-filled syringe, Fasenra
CHU of Nantes, Ministère de la santé - DGOS, Astra-Zeneca France
Severe asthma Asthme sévère, Severe asthma Asthme sévère, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2019-004676-18: Comparison of the mode of action of two anti-asthma drugs, mepolizumab and benralizumab, during treatment of asthma patients with moderate to severe asthma. Vergelijking van de werkingsmechanismen van twee anti-astma medicijnen, mepolizumab en benralizumab, tijdens de behandeling van patiënten met matig tot ernstig astma.

Not yet recruiting
4
72
Europe
Nucala, Fasenra, SB-240563, IW-8405, Solution for injection in pre-filled pen, Nucala, Fasenra
University Medical Center Utrecht, GlaxoSmithKline
severe eosinophilic asthma ernstig eosinofiel astma, Treatment of patients with severe asthma that do not sufficiently respond to current treatment Behandeling van patiënten met ernstig asthma die niet goed op huidige therapie responderen, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
SHAMAL, NCT04159519 / 2019-001924-37: A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Completed
4
168
Europe
Symbicort®, budesonide/formoterol, Fasenra®, benralizumab, Ventolin®, salbutamol
AstraZeneca
Asthma, Severe Eosinophilic Asthma
01/23
01/23
FAST, NCT05384938: FAsenra Safety Trial in India

Completed
4
139
RoW
Benralizumab
AstraZeneca
In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India
07/23
07/23
2020-003358-63: OPTIMAL - Individualized dosetitration of biological treatment in severe asthma

Not yet recruiting
4
150
Europe
Nucala, Fasenra, Cinqaero
Bispebjerg Hospital, Bispebjerg Hospital
Severe asthma, Asthma that requires two or more types of asthma medications, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
EPIPHANY, NCT06385236: Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

Recruiting
4
120
US
Dupilumab, Dupixent, Benralizumab, Fasenra
University of California, San Diego, Mayo Clinic, Yale University, University of Arizona, Harvard University, Brigham and Women's Hospital, National Heart, Lung, and Blood Institute (NHLBI)
Moderate to Severe Asthma
06/27
01/28
BREATH, NCT06288516: BenRalizumab Effect on Airway Remodeling in Severe asTHma

Recruiting
4
45
Europe
Benralizumab 30 mg/ml, biological
Aristotle University Of Thessaloniki, Pulmonary Clinic, Aristotle University of Thessaloniki, Greece, Pulmonary Clinic, University of Ioannina, Pulmonary Clinic, Democritus University of Thrace, 2nd Pulmonary Clinic, Kapodistrian University of Athens, University Hospital of Crete, Pulmonary and Respiratory Failure Department, National and Kapodistrian University of Athens, University Hospital of Patras
Asthma; Eosinophilic, Airway Remodeling
12/25
06/26
BenRex, NCT04102800: Benralizumab Exacerbation Study

Completed
4
157
Europe
Benralizumab
NHS Greater Glasgow and Clyde, University of Glasgow, AstraZeneca, Queen's University, Belfast, Bosch Healthcare Solutions GmbH, InHealthcare, University of Leicester, University of Plymouth, Vitalograph
Asthma
02/24
04/24
BURAN, NCT05552508 / 2022-000152-11: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging

Completed
4
45
Europe, US, RoW
Benralizumab, Fasenra
AstraZeneca
Asthma
07/24
07/24
CHINOOK, NCT03953300 / 2018-003391-13: Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

Recruiting
4
81
Europe, Canada, US
Benralizumab, Placebo
AstraZeneca
Asthma
09/26
09/26
BENRAPRED, NCT04565483: Predictive Signature of Benralizumab Response

Recruiting
4
220
Europe
Benralizumab Prefilled Syringe, Transcriptomic
Nantes University Hospital, AstraZeneca, Ministère de la Santé - France
Asthma; Eosinophilic, Severe Asthma
10/26
11/26
 

Download Options